Kornimate/medical-research-clean huggingface dataset:
enhanced safety laser hair removal system

Conditions: Hirsutism; Hypertrichosis

Summary: the purpose of this study is to determine whether a new laser system provides better safety and efficacy in hair removal than existing lasers.

lasers are a well-established, popular modality for removal of unwanted hair. the existing lasers are based on a wavelength that is specifically absorbed by the pigment melanin found in the hair follicle, where the energy is converted to heat resulting in a thermal injury. however, lasers for hair removal are not without limitations. a laser based long-term hair removal treatment is based on thermal destruction of the hair shaft and follicle using wavelengths that are specifically absorbed by the pigment melanin found in the hair follicle. the heating of hair follicle is done through heat dissipation from the hair shaft. one of the significant limitations of this approach is the fact that the epidermis through which the light energy must penetrate is rich in melanin and therefore absorbs a major portion of the energy, resulting in inadequate heating of the hair follicles. the purpose of the study is an evaluation safety and efficacy of a new laser based device.

Eligibility criteria:
inclusion criteria: * age between 18 and 75 years old * fitzpatrick skin types i to vi exclusion criteria: * age below 18 or above 75 year old * use of photosensitive medications * photosensitive diseases * active infection of any type and active infection or or a history of herpes simplex in the treated site * exposure to sun or artificial tanning during the last 3-4 weeks

Keywords: hirsutism hypertrichosis
evaluate the efficacy of maintenance treatment with capecitabine plus apatinib in advanced gastric cancer

Conditions: Gastric Cancer

Summary: this is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of maintenance treatment with capecitabine plus apatinib, apatinib and observation after first-line xelox/sox chemotherapy for patients with advanced gastric cancer


Eligibility criteria:
inclusion criteria: 1. aged 18-75； 2. had histologically confirmed unresectable and/or metastatic (primary or recurrent) adenocarcinoma of the stomach or gastroesophageal junction； 3. received 4-6 cycles of xelox/sox regimens as first-line chemotherapy and the response was not progression disease (pd); 4. ecog 0-2； 5. patients were tested for tumor her2 status before treatment, and patients with her2-negative disease； 6. presence of at least one measurable lesion according to response evaluation criteria in solid tumors (recist) version 1.1 guidelines； 7. subjects has to voluntarily join the study and sign the informed consent form for the study; 8. adequate organ function as defined below: hematologic anc ≥ 2\*109/l, platelets ≥ 100\*109/l, ast and alt ≤ 2.5×uln, tbil ≤ 1.5×uln 9. receiving no form of chemotherapy, targeted therapy or other study medication; exclusion criteria: 1. previous radiotherapy to the abdomen； 2. previous treatment for advanced disease (neoadjuvant chemotherapy was permitted if administered \>6 months before enrollment)； 3. pregnant or lactating women or women of childbearing potential； 4. disease progression during the first-line chemotherapy; 5. active gastrointestinal bleeding, arterial thrombosis or cerebrovascular accident within 6 months before enrollment 6. previous treatment of apatinib and ramucirumab

Keywords: advanced gastric cancer, apatinib, capecitabine, maintenance
expanding phase iii study of tyroserleutide for injection

Conditions: Hepatocellular Carcinoma

Summary: this is a randomized, double-blinded, placebo-controlled, multi-center clinical trial. patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment groups：6mg/d tyroserleutide (injection), or placebo

* the first stage includes evaluation of subjects, to assess the inclusion criteria and exclusion criteria, based on the patients' preoperative imaging results, including tumor size, tumor characteristics, etc. * in the second stage, subjects will return to the hospital 21 days following the baseline examination.the investigator will determine whether the subject satisfies all inclusion/exclusion criteria. if all requirements are satisfied, then randomization will occur 21 days after surgery * the day of randomization will be defined as day 0. randomized subjects will return to the hospital and begin cycle 1 on the day of randomization (day 0). and the relevant laboratory tests will be performed within 3 days after the end the study drug infusion. * cycles will occur as follows: cycles 2, 3, 4, 5, and n will begin on days 42±3, 70±3, 98±3, 126±3, and 14+28（n-1)± 3, respectively. * based therapeutic drugs are gan fu le * the participant will receive medical inspection so as to observe and ensure drug safety.

Eligibility criteria:
inclusion criteria: * signed informed consent * aged ≥ 18 years and ≤ 75 years old, male or female * subject underwent resection of hepatocellular carcinoma (confirmed by pathology) * the tumor characteristics must meet the following:a single tumor with a maximum diameter \>5cm ,preoperative imaging, or intraoperative visual observation.; exclusion criteria: * concomitant malignant tumor(s) in other systems is/are present * tumor thrombosis in the branch of portal vein or in hepatic vein is detected by preoperative imaging or observed during the surgery * the subject received any previous systemic anti-hcc therapy prior to the resection surgery (except the resection surgery), such as liver transplantation, intervention, ablation, radiotherapy, chemotherapy, molecular targeted therapy or other anti-hcc therapy * the subject took sorafenib prior to randomization * the subject took other study/investigational drugs 7 days prior to randomization * the subject took kang laike injection/soft capsule，or jinke huaier granule 7 days prior to randomization * the subject has central nervous system disease, mental illness, unstable angina, congestive heart failure, severe arrhythmia or other severe uncontrolled diseases * the subject has history of investigational drug or similar drug allergy * the baseline examination indicates that infection, bleeding, bile leakage, or other postoperative complications are present * the subject is pregnant, lactating, or urine pregnancy test result is positive * baseline (post-resection) examination exist tumor recurrence or metastasis;
a non-interventional ambispective real-world cohort of refractory and relapsed (r/r) flt3 mutated acute myeloid leukemia (aml) patients treated with gilteritinib in france

Conditions: Refractory AML; Relapsed Adult AML; FLT3-TKD Mutation; FLT3-ITD

Summary: gilteritinib is available in early access in france through temporary authorisation of use (or atu program) since march 2019. the atu program reflects a real-life treatment situation and the related clinical data would help to better understand the benefit/risk profile of gilteritinib and to better document gilteritinib efficacy and safety in patients who received midostaurine in first line (1l) setting. the main objective is to describe gilteritinib effectiveness in flt3 (fms related tyrosine kinase 3) -mutated aml patients in refractory/relapsed(r/r) situation treated in the context of early access program to gilteritinib in france through temporary authorisation of use, the so-called atu program, and the post atu period from marketing authorisation to launch when reimbursement and price are published.


Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years at aml diagnosis * patients that started gilteritinib during atu and post-atu period from 19th march 2019 to 30th march2021 * patients diagnosed with refractory or relapsed aml as defined by the world health organization (who) classification * patients with flt3 genetic testing performed at diagnosis and/or at r/r (if available) * gilteritinib with or without other drug (chemotherapy, hypomethylating agent, hydroxyurea, etc.) exclusion criteria: * newly diagnosed aml patients * participant opposed to the collection and analysis of their medical data * prescription of gilteritinib out of the scope of its marketing authorisation approval such as post hsct maintenance in patients in first complete remission after intensive chemotherapy * persons placed in curatorship,guardianship or guardianship orders
optimizing an integrated mind and body treatment for insomnia: the sleeps study

Conditions: Insomnia Disorder

Summary: this single-arm feasibility trial will provide digital cognitive behavioral therapy for insomnia (cbt-i) and passive body heating (pbh) sessions using a sauna blanket over a 9-week treatment period to adults aged 18 years or older with insomnia disorder.

insomnia disorder is a common and consequential mental health problem, with prevalence estimates at approximately 10%. the american college of physicians recommends cognitive behavioral therapy for insomnia (cbt-i), an efficacious "mind" (psychological and behavioral) treatment, as the first-line treatment for adults with insomnia. yet, about half of individuals experience residual insomnia symptoms after cbt-i. accordingly, researchers have sought to augment cbt-i, primarily with pharmacotherapy, but many people do not want to use pharmacologic agents due to concerns about side effects and dependence. passive-body heating (pbh), a "body" treatment, involves heating the body via hot baths or showers, infrared sauna, or other heat sources. pbh has been found to reduce the time needed to fall asleep and to improve sleep quality. pbh may improve sleep by increasing skin temperature and decreasing core body temperature, a dynamic associated with sleep onset. cbt-i and pbh thus target distinct factors that may contribute to insomnia, and the investigators hypothesize that the combination of cbt-i and pbh holds promise as a multi-component treatment for insomnia disorder.

Eligibility criteria:
inclusion criteria: * 18 years or older * english-speaking * willing to use birth control if assigned female sex at birth * location to plug sauna blanket into regular wall outlet * ability to lie in sauna blanket for 15 minutes * ability to fit in the sauna blanket (no taller than 6' 3", no greater than 250 lbs) * daily access to the internet via computer, smartphone, or tablet * elevated insomnia symptoms as indexed by a score of 11 or greater on the insomnia severity index (isi) * insomnia disorder (characterized by difficulty initiating sleep) as indexed by a positive diagnosis on the structured clinical interview for dsm-5 sleep disorders (scisd) exclusion criteria: * night shift worker * current or planned routine body heating practices (e.g., saunas, hot tubs) * pregnant or plans to become pregnant during the participation period * other diagnosed sleep disorders or suspected sleep disorders * medical conditions that might increase the risk of passive body heating using an infrared sauna blanket * mental health disorder that may better explain insomnia, require priority treatment, or be exacerbated by time in bed restriction

Keywords: passive body heating cognitive behavioral therapy for insomnia cbt-i mood disorders insomnia disorder digital intervention
early resuturing versus expectant management following perineal wound dehiscence among women who had a vaginal delivery

Conditions: Wound; Perineal Rupture, Dehiscence

Summary: women who deliver their baby vaginally often suffer from a perineal wound. the wound is after being sutured sometimes dehisced after days up to a few weeks and this study will investigate whether it is better to resuture early or leave the rupture for secondary healing.

140 women will be included in the trial, 70 women will be randomized to resuturing and 70 women will be randomized to expectant management. the investigators will follow the women with clinical investigations after 2 and 4 weeks. after two weeks the healing will be measured using the reeda scale and the women will be asked whether they breastfeed or not. the psychological wellbeing will be measured using the epds (edinburgh postnatal depression scale). after four weeks the above will be done again as well as collecting of the daily pain diary that the women have filled in since being included in the trial. after one year the women will be seen again and the investigators will do a clinical investigation including ultrasound of the perineal body, measurement of the perineal body, pop-q ( pelvic organ prolapse quantification system) as well as multiple validated scales as epds, fsfi ( female sexual function index), pfiq (pelvic floor impact questionnaire) and pfdi (pelvic floor distress inventory). these scales will help the investigators to find out if the women have moderate to much trouble with vaginal wideness and/ or moderate to much problems during defecation and therefore, if the perineal body is palpated smaller than 2 cm, there will be indication for a perineal reconstruction. the primary outcome will be to investigate whether early resuturing is reducing the need of a later secondary reconstruction of the perineal body compared with conservative management concerning dehisced perineal wounds. the secondary outcomes will be to investigate whether early resuturing is reducing the risk of having symptoms from the perineum and/or sexual problems one year after delivery. the healing of the wound and the estimated pain will be compared between the two groups. certain questions concerning secondary fear of childbirth will also be asked and compared between the two groups.

Eligibility criteria:
inclusion criteria: * woman over 18 years old who had a vaginal delivery and suffered from a perineal rupture, grade 2 (spontaneous or episiotomy). * no longer than two weeks has passed since delivery. * the woman must be able to give informed consent. exclusion criteria: * perineal rupture grade 3 and 4. * woman suffering from connective tissue disease. * ongoing treatment with oral cortisone or other immunosuppressive disease. * diabetes treated with insulin. * suspicion of occult damage of the anal sphincter. * earlier surgery of the perineum.
usage of biological patch versus plastic in the laparoscopic repair of hiatal hernias

Conditions: Hiatal Hernia

Summary: the purpose of this study is to observe the effective and safety in the laparoscopic repair of hiatal hernia using biological patch versus plastic.

observation indicator: 1. incidence rate of complications, 2. postoperative hospital stay 3. readmission rate in 1st month after operation 4. recurrence rate after operation 5. hospitalization costs 6. self-evaluation of gastroesophageal reflux symptoms and quality of life(qol) in 6th-month, 1st-year,2nd-year,3rd-year,4th-year and 5th-year after operation

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hiatal hernia * consistent with operation indications throughout the guideline of hiatal hernia by the chinese medical association in 2003 * randomly select patch agreed by patients and family members exclusion criteria: * poor general condition * severe organ dysfunction * no-tolerate anesthesia * no-suitable for operation * emergency operation needed * serious adverse events appeared during the operation * sever intraperitoneal adhesion existed * glucocorticoid with long-term use * immunocompromised patients * spirit disease patients * automatically exit * women who pregnant
can medical personnel properly proceed in the case of a patient with bradycardia?

Conditions: Bradycardia

Summary: the study aims to assess the regularity of the proceedings in the case of a patient with bradycardia ecg.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * maximum 1 year of work experience in medicine * paramedics, nurses, physicians exclusion criteria: * not meet the above criteria * wrist or low back diseases * pregnancy
tenotomy or tenodesis of long head biceps in arthroscopic rotator cuff repair

Conditions: Rotator Cuff Syndrome

Summary: during arthroscopic rotator cuff (infraspinatus/supraspinatus) repair, biceps tendon lesions are frequently encountered. however, the most optimal treatment of the diseased long head of the biceps (lhb) tendon during rotator cuff repair remains a topic of debate: tenotomy or tenodesis. the hypothesis is that there is no difference in functional outcome between lhb tenotomy and lhb tenodesis when performed in adjunct to arthroscopic rotator cuff repair.

patients older than 50 years with a supraspinatus and/or infraspinatus tendon rupture sized smaller than 3cm, who are encountered with lhb pathology, will be randomized to either lhb tenotomy or lhb tenodesis. clinical and self-reported data will be collected pre-operatively, and 6 weeks, 3 months, and 1 year after surgery. primary outcome is overall shoulder function evaluated with the constant score. as additional measures of shoulder function, the dutch oxford shoulder test and the disabilities of the arm shoulder and hand questionnaire will be assessed. other evaluations include cosmetic appearance evaluated by the ''popeye'' deformity, arm cramping pain, elbow flexion strength, mri evaluation, quality of life, and cost of surgery. to detect non-inferiority with a one-sided, two-sample t-test with a 80% power and a significance level (alpha) of 0.025, the required sample size is 98 patients.

Eligibility criteria:
inclusion criteria: * patients older than 50 years * degenerative rotator cuff lesion of supraspinatus/infraspinatus tendon, smaller than three centimeter. * patients need to be able to read and write in dutch or english language in order to complete the questionnaires, and sign informed consent. exclusion criteria: * acute, traumatic or partial thickness rotator cuff rupture, or in case a full thickness tear is larger than 3 cm measured using an arthroscopic ruler. * accompanying subscapularis tendon lesion * hour-glass deformation bicepstendon origin or in case of accompanying subscapularis tendon rupture. * osteoarthritis of the glenohumeral joint * acromion to humeral head distance measuring 6mm or smaller. * prior surgery to the involved shoulder * dementia or inability to complete questionnaires and assessments

Keywords: popeye long head biceps tendon arthroscopy functional result
acute phase reactions and thrombophilia in pediatric patients with migraine

Conditions: Migraine; Thrombophilia

Summary: acute migraine attacks can be related to vascular or coagulation activation. previous studies found relative high incidence of prothrombotic events in migraine. the present study intends to assess the coagulation system and activation in patients with migraine during steady state phase and at the beginning of attacks and after 72 hours. a control group of patients with another acute neurologic event like convulsions will be also studied. patients will be at pediatric age and teenagers.


Eligibility criteria:
inclusion criteria: * patients at the pediatric age (5 to 20 ys old) suffering from migraine attacks diagnosed by a neurologist. exclusion criteria: * patients with other underlying neurological conditions of coagulation diseases

Keywords: coagulation
microsatellite instability in colorectal cancers

Conditions: Colorectal Cancer; Colorectal Carcinoma; Microsatellite Instability High; Microsatellite Instability Low; Microsatellite Instability-High

Summary: in this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (msi) compared to microsatellite stable (mss) in patients who underwent surgery for colorectal cancer. we also planned to determine how msi affects prognostic parameters.

according to global cancer statistics, higher than 1.9 million new cases of colorectal cancer (crc) and 935,000 deaths are estimated to occur in 2020, representing about one in 10 cancer cases and deaths. overall, it ranks third in colorectal incidence but second in mortality. in crc evolution, the acquisition of genomic instability is a critical point, and there are at least two different pathways in the pathogenesis of crc: the chromosomal instability (cin) pathway (85%) and the microsatellite instability (msi) pathway (15%). microsatellite instability (msi) is a phenotype that occurs due to a malfunction in the dna repair mechanism and is seen in approximately 15% of colorectal cancers (crcs). crcs with msi have different clinical features, such as a tendency to settle in the proximal colon, poor differentiation, and more lymphocytic infiltration in the tumor. it has been shown that crcs with msi have a better prognosis and respond differently to chemotherapy than crcs with microsatellite stable (mss). we aimed to evaluate the different histopathological features of tumors with msi compared to mss in patients who underwent surgery for colorectal cancer. we also planned to determine how msi affects prognostic parameters such as mortality rate, recurrence, disease-free survival, cancer-specific survival, and overall survival.

Eligibility criteria:
inclusion criteria: * colorectal surgery patients * complete follow-up information exclusion criteria: * whose msi status was not studied in the pathology material * missing follow-up information * colorectal resection for non-neoplastic diseases

Keywords: colorectal cancer prognostic factor microsatellite instability prognosis survival
clinical presentation, and treatment outcomes in tuberculous patients in sohag governorate

Conditions: Tuberculosis

Summary: tuberculosis (tb) is an infectious disease that commonly affects the lung and is caused by a bacterium called mycobacterium tuberculosis. the bacterium mostly affects people with impaired immunity tb becomes the second leading cause of morbidity and mortality among infectious diseases, following the emergence of the human immunodeficiency virus (hiv). hiv is the commonest risk factor for developing a life-threatening tuberculosis disease, on the other hand, hiv related immunodeficiency is worsened by tb infection.tb is among the top 10 causes of death worldwide. in2019, among 8.8 million adults who developed tb disease, 36% were women .tb has become the fifth leading cause of death among women.


Eligibility criteria:
inclusion criteria: * age above 18ys. * confirmed diagnosis of tuberculosis. exclusion criteria: * childern. * not confirmed diagnosis of tuberculosis.